Phase I Study of WX-037 alone, and with WX-554 in Solid Tumours

• Research type

  Research Study

• Full title

  A Phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the PI3K inhibitor WX-037, given as a single agent and in combination with the MEK inhibitor WX-554, in patients with solid tumours

• IRAS ID

  121773

• Contact name

  Udai Banerji

• Contact email

  udai.banerji@icr.ac.uk

• Sponsor organisation

  WILEX AG

• Eudract number

  2012-004552-11

• ISRCTN Number

  xx

• REC name

  London - Chelsea Research Ethics Committee

• REC reference

  13/LO/0310

• Date of REC Opinion

  18 Apr 2013

• REC opinion

  Further Information Favourable Opinion